You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
AstraZeneca's EGFR-inhibitor has now demonstrated an 'overwhelming' disease-free survival and CNS recurrence benefit, but overall survival benefit remains unknown.
The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.
NICE is reversing its earlier negative recommendation for the lung cancer drug after AstraZeneca agreed to provide it at a discount.
The final GioTag data suggests a survival benefit with the regimen among patients with EGFR-mutant NSCLC harboring acquired T790M resistance mutations.
Outcomes from the US cohort of the GioTag study confirm the benefit of Tagrisso for NSCLC patients who have become resistant to first-line Gilotrif.
Researchers reported a correlation between ctDNA clearance and progression-free survival in EGFR-positive, MET-amplified patients treated with Tagrisso and savolitinib.
The results of the randomized Phase III ADAURA trial was unblinded early due to "overwhelming efficacy" in lung cancer patients.
In a Phase I trial, non-small cell lung cancer patients with exon 20 insertions experienced durable responses with amivantamab.
The company will now initiate the dose escalation portion of a Phase I/II study and will enroll 90 NSCLC patients in the country.
The company maintained that poziotinib could provide clinical benefit in EGFR exon 20-mutated NSCLC and are adjusting trial designs in the hopes of maximizing its efficacy.